<DOC>
	<DOC>NCT00975104</DOC>
	<brief_summary>Randomized, Double-blind, Placebo-controlled Dose Ranging Study to Evaluate the Safety and Efficacy of AMG 745 in Age-associated Muscle Loss</brief_summary>
	<brief_title>AMG 745 in Subjects With Age-associated Muscle Loss</brief_title>
	<detailed_description />
	<criteria>Limited exercise tolerance and Rapid Assessment of Physical Activity (RAPA) score ≤ 3 Hand grip (dominant hand): men ≤ 30.3 kg, women ≤ 19.3 kg Walk speed ≤ 0.8 m/s (based on a 4 meter walk) Subject weight &gt; 137 kg (300 lbs), or Body Mass Index (BMI) &gt; 32 kg/m2 Primary muscle disease or myopathy Recent immobilization, or major trauma to the legs within 6 months Knee or hip replacement within 12 months or lower extremity amputation Significant laboratory abnormalities Significant comorbidities or medical history Weight loss (intentional or unintentional) of &gt; 5 kg in 12 weeks Unable to complete an MRI scan</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Aging</keyword>
	<keyword>Frailty</keyword>
	<keyword>Sedentary</keyword>
	<keyword>Immobilization</keyword>
	<keyword>Atrophy</keyword>
	<keyword>Muscle Wasting</keyword>
	<keyword>Physical Activity</keyword>
</DOC>